Interleukin-6 Gene Ablation in a Transgenic Mouse Model of Malignant Skin Melanoma
- 31 March 2005
- journal article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 166 (3), 831-841
- https://doi.org/10.1016/s0002-9440(10)62304-8
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathwaysOncogene, 2003
- ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosisOncogene, 2003
- Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesisOncogene, 2002
- An inhibitor of PI3-K differentially affects proliferation and IL-6 protein secretion in normal and leukemic myeloid cells depending on the stage of differentiationExperimental Hematology, 2000
- Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanomaOncogene, 1999
- Ultraviolet B radiation-induced production of interleukin 1α and interleukin 6 in a human squamous carcinoma cell line is wavelength-dependent and can be inhibited by pharmacological agentsBritish Journal of Dermatology, 1998
- Synergistic induction of metallothionein synthesis by interleukin-6, dexamethasone and zinc in the ratInternational Journal of Immunopharmacology, 1996
- Impaired immune and acute-phase responses in interleukin-6-deficient miceNature, 1994
- Localization of Metallothionein in Hair Follicles of Normal Skin and the Basal Cell Layer of Hyperplastic Epidermis: Possible Association with Cell ProliferationJournal of Investigative Dermatology, 1991
- Proline analogue removes fibroblasts from cultured mixed cell populationsNature, 1977